Patents by Inventor Benjamin M. Hutchins
Benjamin M. Hutchins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230391733Abstract: The invention relates to novel methods of preparing cell-binding agent-cytotoxic agent conjugates, wherein the cytotoxic agent is an imine-containing cytotoxic agent bearing a maleimide group. In some embodiments, the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU/OU numbering position 442 (or C442) on an antibody CBA. The invention also provides conjugates prepared by the methods of the present invention, compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.Type: ApplicationFiled: December 30, 2022Publication date: December 7, 2023Applicant: IMMUNOGEN, INC.Inventors: Scott A. Hilderbrand, Benjamin M. Hutchins
-
Patent number: 11572349Abstract: The invention relates to novel methods of preparing cell-binding agent-cytotoxic agent conjugates, wherein the cytotoxic agent is an imine-containing cytotoxic agent bearing a maleimide group. In some embodiments, the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU/OU numbering position 442 (or C442) on an antibody CBA. The invention also provides conjugates prepared by the methods of the present invention, compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.Type: GrantFiled: September 17, 2020Date of Patent: February 7, 2023Assignee: IMMUNOGEN, INC.Inventors: Scott A. Hilderbrand, Benjamin M. Hutchins
-
Publication number: 20220267371Abstract: Methods of producing, purifying, and formulating antibody drug conjugates (ADCs) are provided herein. The methods use continuous conjugation processes, single-pass tangential flow filtration, countercurrent diafiltration, and/or in-line process automation technologies. The methods decrease process times and costs and improve product consistency.Type: ApplicationFiled: February 8, 2022Publication date: August 25, 2022Inventors: Daniel F. MILANO, Michael R. REARDON, Richard A. SILVA, Benjamin M. HUTCHINS, Robert W. HERBST
-
Publication number: 20220202947Abstract: The present invention generally relates to methods of preventing methionine oxidation in immunoconjugates. The present invention also relates to pharmaceutical compositions of immunoconjugates in which the amount of methionine oxidation is minimized.Type: ApplicationFiled: December 13, 2021Publication date: June 30, 2022Inventors: Michael Fleming, Amit Gangar, Nicholas C. Yoder, Chen Bai, Scott A. Hilderbrand, Benjamin M. Hutchins
-
Patent number: 11274121Abstract: Methods of producing, purifying, and formulating antibody drug conjugates (ADCs) are provided herein. The methods use continuous conjugation processes, single-pass tangential flow filtration, countercurrent diafiltration, and/or in-line process automation technologies. The methods decrease process times and costs and improve product consistency.Type: GrantFiled: January 11, 2019Date of Patent: March 15, 2022Assignee: ImmunoGen, Inc.Inventors: Daniel F. Milano, Michael R. Reardon, Richard A. Silva, Benjamin M. Hutchins, Robert W. Herbst
-
Publication number: 20210101871Abstract: The invention relates to novel methods of preparing cell-binding agent-cytotoxic agent conjugates, wherein the cytotoxic agent is an imine-containing cytotoxic agent bearing a maleimide group. In some embodiments, the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU/OU numbering position 442 (or C442) on an antibody CBA. The invention also provides conjugates prepared by the methods of the present invention, compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.Type: ApplicationFiled: September 17, 2020Publication date: April 8, 2021Applicants: IMMUNOGEN, INC., IMMUNOGEN, INC.Inventors: Scott A. Hilderbrand, Benjamin M. Hutchins
-
Patent number: 10822313Abstract: The invention relates to novel methods of preparing cell-binding agent-cytotoxic agent conjugates, wherein the cytotoxic agent is an imine-containing cytotoxic agent bearing a maleimide group. In some embodiments, the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU/OU numbering position 442 (or C442) on an antibody CBA. The invention also provides conjugates prepared by the methods of the present invention, compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.Type: GrantFiled: October 30, 2019Date of Patent: November 3, 2020Assignee: IMMUNOGEN, INC.Inventors: Scott A. Hilderbrand, Benjamin M. Hutchins
-
Publication number: 20200157056Abstract: The invention relates to novel methods of preparing cell-binding agent-cytotoxic agent conjugates, wherein the cytotoxic agent is an imine-containing cytotoxic agent bearing a maleimide group. In some embodiments, the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU/OU numbering position 442 (or C442) on an antibody CBA. The invention also provides conjugates prepared by the methods of the present invention, compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.Type: ApplicationFiled: October 30, 2019Publication date: May 21, 2020Inventors: Scott A. Hilderbrand, Benjamin M. Hutchins
-
Publication number: 20200101168Abstract: The present invention provides a novel process for preparing a cell-binding agent cytotoxic agent conjugate. The process comprises the steps of: (a) reacting a cytotoxic agent with a bifunctional crosslinking reagent represented by the following structural formula: or a salt thereof, in a buffer solution comprising a buffering agent to provide a first mixture comprising a cytotoxic agent-linker compound, wherein the buffer solution has high buffer capacity; and (b) reacting the first mixture comprising the cytotoxic agent-linker compound from step (a) with a cell-binding agent in a solution having a pH of 4 to 9 to provide a second mixture comprising the cell-binding agent cytotoxic agent conjugate. The cell-binding agent cytotoxic agent conjugates prepared according to the processes described herein are also included in the present invention.Type: ApplicationFiled: August 7, 2019Publication date: April 2, 2020Inventor: Benjamin M. Hutchins
-
Patent number: 10494348Abstract: The invention relates to novel methods of preparing cell-binding agent-cytotoxic agent conjugates, wherein the cytotoxic agent is an imine-containing cytotoxic agent bearing a maleimide group. In some embodiments, the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU/OU numbering position 442 (or C442) on an antibody CBA. The invention also provides conjugates prepared by the methods of the present invention, compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.Type: GrantFiled: March 26, 2019Date of Patent: December 3, 2019Assignee: IMMUNOGEN, INC.Inventors: Scott A. Hilderbrand, Benjamin M. Hutchins
-
Publication number: 20190315699Abstract: The invention relates to novel methods of preparing cell-binding agent-cytotoxic agent conjugates, wherein the cytotoxic agent is an imine-containing cytotoxic agent bearing a maleimide group. In some embodiments, the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU/OU numbering position 442 (or C442) on an antibody CBA. The invention also provides conjugates prepared by the methods of the present invention, compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.Type: ApplicationFiled: March 26, 2019Publication date: October 17, 2019Inventors: Scott A. Hilderbrand, Benjamin M. Hutchins
-
Patent number: 10413615Abstract: The present invention provides a novel process for preparing a cell-binding agent cytotoxic agent conjugate. The process comprises the steps of: (a) reacting a cytotoxic agent with a bifunctional crosslinking reagent represented by the structural formula (I) or a salt thereof, in a buffer solution comprising a buffering agent to provide a first mixture comprising a cytotoxic agent-linker compound, wherein the buffer solution has high buffer capacity; and (b) reacting the first mixture comprising the cytotoxic agent-linker compound from step (a) with a cell-binding agent in a solution having a pH of 4 to 9 to provide a second mixture comprising the cell-binding agent cytotoxic agent conjugate. The cell-binding agent cytotoxic agent conjugates prepared according to the processes described herein are also included in the present invention.Type: GrantFiled: November 18, 2015Date of Patent: September 17, 2019Assignee: IMMUNOGEN, INC.Inventor: Benjamin M. Hutchins
-
Publication number: 20190270769Abstract: Methods of producing, purifying, and formulating antibody drug conjugates (ADCs) are provided herein. The methods use continuous conjugation processes, single-pass tangential flow filtration, countercurrent diafiltration, and/or in-line process automation technologies. The methods decrease process times and costs and improve product consistency.Type: ApplicationFiled: January 11, 2019Publication date: September 5, 2019Inventors: Daniel F. Milano, Michael R. Reardon, Richard A. Silva, Benjamin M. Hutchins, Robert W. Herbst
-
Patent number: 10287256Abstract: The invention relates to novel methods of preparing cell-binding agent-cytotoxic agent conjugates, wherein the cytotoxic agent is an imine-containing cytotoxic agent bearing a maleimide group. In some embodiments, the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU/OU numbering position 442 (or C442) on an antibody CBA. The invention also provides conjugates prepared by the methods of the present invention, compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.Type: GrantFiled: November 22, 2017Date of Patent: May 14, 2019Assignee: IMMUNOGEN, INC.Inventors: Scott A. Hilderbrand, Benjamin M. Hutchins
-
Publication number: 20190111147Abstract: The present invention generally relates to methods of preventing methionine oxidation in immunoconjugates. The present invention also relates to pharmaceutical compositions of immunoconjugates in which the amount of methionine oxidation is minimized.Type: ApplicationFiled: September 21, 2018Publication date: April 18, 2019Inventors: Michael Fleming, Amit Gangar, Nicholas C. Yoder, Chen Bai, Scott Alan Hilderbrand, Benjamin M. Hutchins
-
Publication number: 20180208562Abstract: The invention relates to novel methods of preparing cell-binding agent-cytotoxic agent conjugates, wherein the cytotoxic agent is an imine-containing cytotoxic agent bearing a maleimide group. In some embodiments, the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU/OU numbering position 442 (or C442) on an antibody CBA. The invention also provides conjugates prepared by the methods of the present invention, compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.Type: ApplicationFiled: November 22, 2017Publication date: July 26, 2018Inventors: Scott A. Hilderbrand, Benjamin M. Hutchins
-
Publication number: 20170354742Abstract: The present invention provides a novel process for preparing a cell-binding agent cytotoxic agent conjugate. The process comprises the steps of: (a) reacting a cytotoxic agent with a bifunctional crosslinking reagent represented by the structural formula(I) or a salt thereof, in a buffer solution comprising a buffering agent to provide a first mixture comprising a cytotoxic agent-linker compound, wherein the buffer solution has high buffer capacity; and (b) reacting the first mixture comprising the cytotoxic agent-linker compound from step (a) with a cell-binding agent in a solution having a pH of 4 to 9 to provide a second mixture comprising the cell-binding agent cytotoxic agent conjugate. The cell-binding agent cytotoxic agent conjugates prepared according to the processes described herein are also included in the present invention.Type: ApplicationFiled: November 18, 2015Publication date: December 14, 2017Inventor: Benjamin M. Hutchins